Literature DB >> 24893003

Phage neutralization by sera of patients receiving phage therapy.

Marzanna Łusiak-Szelachowska, Maciej Zaczek, Beata Weber-Dąbrowska, Ryszard Międzybrodzki, Marlena Kłak, Wojciech Fortuna, Sławomir Letkiewicz, Paweł Rogóż, Krzysztof Szufnarowski, Ewa Jończyk-Matysiak, Barbara Owczarek, Andrzej Górski.   

Abstract

The aim of our investigation was to verify whether phage therapy (PT) can induce antiphage antibodies. The antiphage activity was determined in sera from 122 patients from the Phage Therapy Unit in Wrocław with bacterial infections before and during PT, and in sera from 30 healthy volunteers using a neutralization test. Furthermore, levels of antiphage antibodies were investigated in sera of 19 patients receiving staphylococcal phages and sera of 20 healthy volunteers using enzyme-linked immunosorbent assay. The phages were administered orally, locally, orally/locally, intrarectally, or orally/intrarectally. The rate of phage inactivation (K) estimated the level of phages' neutralization by human sera. Low K rates were found in sera of healthy volunteers (K ≤ 1.73). Low K rates were detected before PT (K ≤ 1.64). High antiphage activity of sera K > 18 was observed in 12.3% of examined patients (n = 15) treated with phages locally (n = 13) or locally/orally (n = 2) from 15 to 60 days of PT. High K rates were found in patients treated with some Staphylococcus aureus, Pseudomonas aeruginosa, and Enterococcus faecalis phages. Low K rates were observed during PT in sera of patients using phages orally (K ≤ 1.04). Increased inactivation of phages by sera of patients receiving PT decreased after therapy. These results suggest that the antiphage activity in patients' sera depends on the route of phage administration and phage type. The induction of antiphage activity of sera during or after PT does not exclude a favorable result of PT.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24893003      PMCID: PMC4076984          DOI: 10.1089/vim.2013.0128

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  8 in total

Review 1.  Clinical aspects of phage therapy.

Authors:  Ryszard Międzybrodzki; Jan Borysowski; Beata Weber-Dąbrowska; Wojciech Fortuna; Sławomir Letkiewicz; Krzysztof Szufnarowski; Zdzisław Pawełczyk; Paweł Rogóż; Marlena Kłak; Elżbieta Wojtasik; Andrzej Górski
Journal:  Adv Virus Res       Date:  2012       Impact factor: 9.937

Review 2.  Phage as a modulator of immune responses: practical implications for phage therapy.

Authors:  Andrzej Górski; Ryszard Międzybrodzki; Jan Borysowski; Krystyna Dąbrowska; Piotr Wierzbicki; Monika Ohams; Grażyna Korczak-Kowalska; Natasza Olszowska-Zaremba; Marzena Łusiak-Szelachowska; Marlena Kłak; Ewa Jończyk; Ewelina Kaniuga; Aneta Gołaś; Sylwia Purchla; Beata Weber-Dąbrowska; Sławomir Letkiewicz; Wojciech Fortuna; Krzysztof Szufnarowski; Zdzisław Pawełczyk; Paweł Rogóż; Danuta Kłosowska
Journal:  Adv Virus Res       Date:  2012       Impact factor: 9.937

3.  Immunogenic effect of bacteriophage in patients subjected to phage therapy.

Authors:  A Kucharewicz-Krukowska; S Slopek
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  1987       Impact factor: 4.291

4.  Antibodies against staphylococcal bacteriophages in human sera. II. Assay of antibodies in exacerbation and regression of chronic staphylococcal osteomyelitis.

Authors:  S A Hedström; C Kamme
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1973-12

5.  The serum antibody response to bacteriophage phi chi 174 in germ-free and conventionally reared mice. II. Kinetics of the serum antibody response following primary immunization.

Authors:  P W Stashak; P J Baker; B S Roberson
Journal:  Immunology       Date:  1970-02       Impact factor: 7.397

6.  Effect of rituximab on human in vivo antibody immune responses.

Authors:  Mark D Pescovitz; Troy R Torgerson; Hans D Ochs; Elizabeth Ocheltree; Paula McGee; Heidi Krause-Steinrauf; John M Lachin; Jennifer Canniff; Carla Greenbaum; Kevan C Herold; Jay S Skyler; Adriana Weinberg
Journal:  J Allergy Clin Immunol       Date:  2011-09-09       Impact factor: 10.793

7.  Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy.

Authors:  Anne Bruttin; Harald Brüssow
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

8.  Antibodies against staphylococcal bacteriophages in human sera. I. Assay of antibodies in healthy individuals and in patients with staphylococcal infections.

Authors:  C Kamme
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1973-12
  8 in total
  54 in total

1.  Immunogenicity studies of proteins forming the T4 phage head surface.

Authors:  Krystyna Dąbrowska; Paulina Miernikiewicz; Agnieszka Piotrowicz; Katarzyna Hodyra; Barbara Owczarek; Dorota Lecion; Zuzanna Kaźmierczak; Andrey Letarov; Andrzej Górski
Journal:  J Virol       Date:  2014-08-20       Impact factor: 5.103

Review 2.  Biological challenges of phage therapy and proposed solutions: a literature review.

Authors:  Katherine M Caflisch; Gina A Suh; Robin Patel
Journal:  Expert Rev Anti Infect Ther       Date:  2019-12-02       Impact factor: 5.091

Review 3.  Phages of life - the path to pharma.

Authors:  Amanda Forde; Colin Hill
Journal:  Br J Pharmacol       Date:  2018-01-03       Impact factor: 8.739

Review 4.  Bacteriophage Therapy for Staphylococcus Aureus Infections: A Review of Animal Models, Treatments, and Clinical Trials.

Authors:  Lucile Plumet; Nour Ahmad-Mansour; Catherine Dunyach-Remy; Karima Kissa; Albert Sotto; Jean-Philippe Lavigne; Denis Costechareyre; Virginie Molle
Journal:  Front Cell Infect Microbiol       Date:  2022-06-17       Impact factor: 6.073

Review 5.  Therapeutics and delivery vehicles for local treatment of osteomyelitis.

Authors:  Leah H Cobb; Emily M McCabe; Lauren B Priddy
Journal:  J Orthop Res       Date:  2020-04-21       Impact factor: 3.494

6.  Phage Therapy for Limb-threatening Prosthetic Knee Klebsiella pneumoniae Infection: Case Report and In Vitro Characterization of Anti-biofilm Activity.

Authors:  Edison J Cano; Katherine M Caflisch; Paul L Bollyky; Jonas D Van Belleghem; Robin Patel; Joseph Fackler; Michael J Brownstein; Bri'Anna Horne; Biswajit Biswas; Matthew Henry; Francisco Malagon; David G Lewallen; Gina A Suh
Journal:  Clin Infect Dis       Date:  2021-07-01       Impact factor: 9.079

7.  Neutralizing antibody response against subcutaneously injected bacteriophages in rabbit model.

Authors:  Archana Archana; Prem Shankar Patel; Rajesh Kumar; Gopal Nath
Journal:  Virusdisease       Date:  2021-03-10

Review 8.  Clinical Pharmacology of Bacteriophage Therapy: A Focus on Multidrug-Resistant Pseudomonas aeruginosa Infections.

Authors:  Dana Holger; Razieh Kebriaei; Taylor Morrisette; Katherine Lev; Jose Alexander; Michael Rybak
Journal:  Antibiotics (Basel)       Date:  2021-05-11

9.  Low Immunogenicity of Intravesical Phage Therapy for Urogenitary Tract Infections.

Authors:  Sławomir Letkiewicz; Marzanna Łusiak-Szelachowska; Ryszard Międzybrodzki; Maciej Żaczek; Beata Weber-Dąbrowska; Andrzej Górski
Journal:  Antibiotics (Basel)       Date:  2021-05-25

10.  Successful Treatment of Staphylococcus aureus Prosthetic Joint Infection with Bacteriophage Therapy.

Authors:  Claudia Ramirez-Sanchez; Francis Gonzales; Maureen Buckley; Biswajit Biswas; Matthew Henry; Michael V Deschenes; Bri'Anna Horne; Joseph Fackler; Michael J Brownstein; Robert T Schooley; Saima Aslam
Journal:  Viruses       Date:  2021-06-21       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.